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Chemical classiﬁcation and Deﬁned Daily Dose (DDD) measure-
ment unit. Data of wholesalers, who are legally obliged provide
this information to the Slovak Institute for Drug Control, was
used for the analysis. The results were expressed in the numbers
of the packages, ﬁnance units (€) and deﬁned daily doses per
1000 inhabitants per day (DID). RESULTS: The collected data
showed a slight increases in consumption of drugs for treatment
of neurological disorder from 1997 to 2006 in term of DID (in
1997 (111.00), in 2001 (111.30) and in 2006 (130.34). A sig-
niﬁcant increase in consumption of psychoanaleptics (in 1997
(13.07), in 2001 (24.69) and in 2006 (39.73) and slight decrease
in consumption of psycholeptics (in 1997 (41.49), in 2001
(40.19) and in 2006 (38.29) in term of DID can be seen from this
analysis. We can see a slight increase in consumption of drugs
in term of DID within the group of antiepileptics (in 1997(4.35),
in 2001 (4.82) and in 2006 (6.19) and anti-parkinson drugs (in
1997(2.78), in 2001 (3.42) and in 2006 (3.60). Financial expen-
ditures for psychoanaleptics (in 1997 (11,211,000 €), in 2001
(26,817,000 €) and in 2006 (24,671,000 €), for psycholeptics (in
1997 (8,149,000 €), in 2001 (14,747,000 €) and in 2006
(28,839,000 €) can be seen in this study. CONCLUSION: Insepa-
rable components of the Slovak drug policy must be viewed
realistically with regard to the consumption of drugs for neuro-
logical disorder.
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OBJECTIVES: To characterize the use of health care services and
the corresponding costs of patients with Neurological Disorders
(ND) managed at Primary Care Settings (PCS) under usual
medical practice. METHODS: A retrospective, multicenter study
was carried out. All patients seen by 5 PCS during year 2006 with
at least one demand for ND care (CIAP-2: component-7) were
included in the analysis. The control group was formed with the
rest of patients without NDs. Outcomes measures included
sociodemographics, comorbidities, Charlson index (severity), use
of health care resources and ambulatory costs (drugs, diagnostic/
therapeutic procedures, referrals and visits). Statistical analysis
included descriptive, logistic regression model and ANCOVA
models. RESULTS: A total of 80,775 patients were included, of
which 19,423 had any ND (24.0%; 95%CI: 23.7 24.3%).
Patients requiring health care for their ND were older
(46.2  22.1 vs. 38.9  22.9, p < 0.001), with increased severity
(0.3  0.6 vs. 0.2  0.5, p < 0.001), predominantly female (63.6
vs. 49.8%, p < 0.001), larger number of health problems
(6.1  4.0 vs. 4.3  3.2, p < 0.001) and increased per patient per
year medical visits (9.9  9.4 vs. 7.2  7.7, p < 0.001) and days
of work absenteeism due to disability (73.3  124.4 vs.
56.8  107.6, p < 0.001). Main symptoms demanding care
were: vertigo/dizziness (25.6%) and headache (17.7%). Neuro-
logical treatment was associated with women (OR = 1.8),
depressive syndrome (OR = 1.5) and cardiovascular events
(OR = 1.2), p < 0.0001 in all cases. Crude and adjusted (age,
gender and comorbidities) mean annual cost were signiﬁcantly
higher in patients with NDs than in controls; €708.25  900.94
vs. €443.10  678.44, p < 0.001, and €932.87 vs. €712.38,
p < 0.001. All per patient per year components of costs (ﬁxed/
semi-ﬁxed, tests, referrals) were signiﬁcantly higher in the ND
group, particularly pharmaceutical expenditure; €621.26 vs.
€479.25) p < 0.001. CONCLUSION: Patients requiring care for
NDs in the primary care setting showed a large number of
comorbidities, increased use of health resources and higher per
patient per year cost.
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OBJECTIVES: To assess lifetime cost-effectiveness of glatiramer
acetate (GA) compared to natalizumab (NZ) in patients diag-
nosed with relapsing-remitting multiple sclerosis (RRMS) in
the presence of long-term clinical evidence. METHODS: A
literature-based Markov model was developed with patients
transitioning through health-states based on Kurtzke expanded
disability status scale (EDSS). Patients in the model are  21
years of age with RRMS and start in any of the health-states at
diagnosis. Patients with an EDSS score below 6.0 receive treat-
ment. Treatment effects for relapse and disease progression were
obtained from clinical trials and long-term clinical evidence
where available. Transition rates were estimated by applying a
percent reduction of treatment effects of therapies to natural
history rates of relapse and disease progression. Rates were
adjusted for treatment discontinuation and persistent NZ anti-
bodies. Patients incurred drug, other medical and lost worker
productivity costs. Patients on NZ incurred additional costs for
monitoring, diagnosis, and treatment of progressive multifocal
leukoencephalopathy (PML), a possible serious adverse event for
patients on NZ. Utility weights for each health-state were taken
from published utility assessments for people with RRMS. The
primary outcomes of the model were lifetime costs and quality-
adjusted life years (QALYs). Costs (2005US$) and outcomes
were discounted at 3% annually. RESULTS: The lifetime costs
per patient for GA were $352,762 and for NZ were $422,210.
QALYs during the lifetime of a patient on GA were 9.303 and
9.300 for a patient on NZ. The incremental cost per QALY for
patients on GA and NZ compared to symptomatic treatment
alone was $258,464 and $580,119 respectively. GA is cost-
saving when compared to NZ. PML had very little impact on
results. CONCLUSION: While incorporating all the long-term
clinical evidence, model results indicated that GA was both less
costly and more effective over a patient’s lifetime than NZ in
treating RRMS.
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OBJECTIVES: To assess the cost effectiveness of long-term treat-
ment with eszopiclone for chronic primary insomnia in adults.
METHODS: We used patient level data from a 6-month, double-
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